blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1



Wednesday, 15 December 2010

Paxil killer Carmichael - mother & brother mentally ill - Paxilprogress

http://paxilprogress.org/forums/showthread.php?t=20308

Killer dad breaks silence




--------------------------------------------------------------------------------

http://lfpress.ca/newsstand/News/Loc...25750-sun.html



Killer dad breaks silence



Wed, August 9, 2006



Carmichael says it's vital not to hide mental illness



By JENNIFER O'BRIEN, FREE PRESS REPORTER



Killing Ian became an obsession - a 'mission'









A sketch shows David Carmichael in court in London in October 2005, as Justice Helen Rady delivers her verdict.

A Toronto man who killed his son in a London hotel room has broken a two-year silence in hopes he can help families afflicted by mental illness avoid similar tragedies.



In a conversation from the Brockville Psychiatric Hospital, David Carmichael said he is haunted every day by memories of the night he killed his 11-year-old son, Ian.



"I wouldn't want any family to go through what our family has. It has been catastrophic and devastating," he said.



"People never recover from losing a child, but losing a child this way . . .



"I'm sorry," Carmichael finished, sobbing into the phone. "I miss my son very much."





Carmichael, 48, contacted The Free Press last week, saying he hopes to help remove the social stigma around mental health issues.



Carmichael also wants to warn people of the dangers of hiding mental illness.



Well-known in Toronto's sports communities, Carmichael was a physical activity and sport consultant who developed programs aimed at getting kids active and into playing sports, regardless of ability or skill. He was former director of national projects at ParticipAction.



He suffered depression and began taking an old antidepressant prescription -- without contacting his doctor -- two weeks before killing Ian on a father-son road trip at the Holiday Inn on Exeter Road in London.



Now, two years later, Carmichael believes that anti-depressant -- Paxil -- is directly linked to the delusions that led him to believe he could protect his family by killing Ian.

"Within a day or two, I was beginning to plan suicides and began thinking my son was going through so much pain himself," he said. "Then I started planning a murder-suicide, and then just murder.



"It became my mission to kill Ian."



Yesterday, a spokesperson for GlaxoSmithKline in Canada, which produces Paxil, said Paxil did not trigger Carmichael's actions.



"David Carmichael's case is certainly a terrible tragedy, however we do not believe Paxil played any part in this situation," said spokesperson Peter Schram.



An Internet search brings up other Paxil patients who claim to have had psychotic episodes related to the drug, but an expert said yesterday the link is doubtful.



"I would have a hard time accepting that the medication caused the psychosis," said Dr. Leonardo Cortese, an associate professor at Western who specializes in antipsychotic medicines.



Cortese said he often prescribes Paxil for depressed patients and that it is one of the most effective antidepressants on the market.



"Psychosis can be associated with depression by itself, and my opinion is that it is often the illness causing it. There is very little evidence to support that the antidepressants would cause it," said Cortese, also clinical director of Specialized Mental Health Programs at Windsor Regional Hospital.



Psychosis is an illness that often includes hallucinations, delusions and irrational thoughts and fears.



There is controversy around some antidepressants, including Paxil, being linked to suicide and to hostile behaviour. In 2001, a U.S. jury awarded $8 million to the family of Donald Schell, a man who killed several family members and himself after taking two Paxil tablets. GlaxoSmithKline has maintained Schell's depression caused him to become homicidal.



Carmichael's wife, Elizabeth Primrose, said Carmichael was "hard to deal with" when he went on Paxil.



"He had always been a steady man. He didn't complain about dinner. He ironed his own clothes. He was easy," she said, even when he was feeling depressed. But when taking his prescription, he became less easygoing.



Carmichael said another aggravating factor is the stigma around mental illness that prevents people from telling friends and family when they're sick.



"If people around me knew . . . they would have known something was wrong. I was obsessed with Ian," he said.



Carmichael, reportedly a loving and involved father, said he began planning to kill on the premise that Ian -- who suffered from epilepsy -- was in a living hell and had permanent brain damage.



Carmichael started to have delusions about Ian's behaviour, imagining Ian would kill his sister and give his mom a nervous breakdown.



"To me, at the time, killing Ian was an act of love and protection," Carmichael said.



He had taken Paxil previously for depression. He had stopped, but resumed on his own in July 2004. When his usual 40 milligram dose of Paxil didn't seem to help, Carmichael upped it to 60 mg.



There is a history of mental illness in Carmichael's family -- both his mother and brother suffer depression, he said.



At his trial in London, Carmichael's brother testified he, too, had once thought of killing a son while depressed.





Media reports over the past year have linked some antidepressants to suicide. And well-known British psychopharmacologist David Healy suggests some antidepressants can cause violent reactions in some users.



While in psychiatric hospital in Brockville, Carmichael has built a website discussing his actions. He said if he had known about potential side-effects of certain antidepressants he would have talked to a doctor first.



WHAT HAPPENED



- July 30, 2004: Carmichael drives his son, Ian, to London to visit an area BMX bike track.



- July 31, 2004: Carmichael kills Ian in hotel room 609 at the Holiday Inn on Exeter Road. He is charged with first-degree murder



- Sept. 26, 2005: Carmichael pleads not guilty to first-degree murder at his London trial, heard by Superior Court Justice Helen Rady. His lawyer is Philip Campbell of Toronto.



- Sept. 30, 2005: Carmichael is found not criminally responsible for the death of his son.



- October 2005: Carmichael is sent to Brockville Psychiatric Hospital, a minimum-security mental health facility

PAXIL - Carmichael,was self-medicating himself with an anti-depressant Seroxat

Carmichael, who was self-medicating himself with an anti-depressant

http://pbdba.lfpress.com/perl-bin/publish.cgi?search=blogs&s_blog_id=12&archive=Live&page=15&x=blogs&s=blogs

The London Free Press


(C) Copyright 2007, Sun Media Corporation

Man who killed his son eager to talk about depression

Wednesday, May 9, 2007



BY IAN GILLESPIE, FREE PRESS COLUMNIST



David Carmichael knows a lot about depression.



Ever since he killed his 11-year-old son in a London hotel almost three years ago, Carmichael has schooled himself obsessively on the topic. Words and phrases like "delirium" and "psychotic depression" and "SSRI-induced psychosis" (selective serotonin reuptake inhibitors) roll easily off his tongue.



And he's eager to talk about it -- on the phone, by e-mail or in his electronic chat room.



I'm just not sure I want to listen.



Carmichael killed his son, Ian, in the morning of July 31, 2004. Ostensibly, they'd come to London to attend a biking event in St. Thomas. But as testimony later revealed, Carmichael, who was self-medicating himself with an anti-depressant, believed his son was brain-damaged and was going to harm Carmichael's wife.



And so he strangled him.



"After he was dead, I moved his body to the centre of the bed, kissed him on the lips and told him, 'I love you, I'm really going to miss you, but you're in a better place now.' I didn't cry."



We know these details, because Carmichael has posted them on his website (www.davidcarmichael.com).



In September 2005, Carmichael was judged "not criminally responsible on account of a mental disorder" and was sent to the Brockville Mental Health Centre. He's still there, but says he's free to leave the facility for about six hours every day -- sometimes on his own, but always under at least indirect supervision.



"I'm living quite a normal life," he says. "I work out every day, I'm involved in a lot of different things. Yeah, I'm keeping very busy."



His website (www.depressionsufferers.com), which he launched Monday to coincide with National Mental Health Week, is filled with information about depression. But the main component is a chat room and message board, where online participants can share their thoughts and feelings about depression.



"Support is a critical piece of recovery," he says. "And I feel that people who've had to fight (depression) and survived it are the people who can give the best advice."



Carmichael admits he has no clinical training in the field (before his son's death, Carmichael was a physical-activity consultant). But he says the information on the website is drawn from experts and has been supported by his psychiatrists and counsellors.



He also emphasizes the first paragraph of his "treatment options" section warns readers: "If you're having thoughts about harming yourself or someone else, get yourself to the emergency department of a local hospital."



But the main purpose of the website, says Carmichael, is to help people with depression realize they're not alone.



"I think all these silent people need to start interacting," he says. "We have to break the silence."



Carmichael says that kind of support might have prevented the death of his son.



"I wish I'd had it," he says. "And if it's not going to come from your own neighbourhood or your own family, then maybe it's going to be online."



He's right, of course. We need to talk more about depression and mental illness. We need to break the shame and stigma surrounding these issues.



But still, I feel uneasy talking to Carmichael because he seems to blame a lot of things for his son's death. He blames depression, he blames the drug Paxil, he blames his "predisposition to mental illness," he blames the family, friends and co-workers who he felt "abandoned" him.



In a way, he even blames you and me when he says, "The public doesn't understand this illness."



I suppose he's right. But a lot of people suffer from depression. A lot of people have problems with pills. A lot of people feel alone and isolated.



But most of them don't kill their son, then post details on the Internet of how they did it and then set themselves up as some kind of heroic crusader for mental health.



"I've forgiven myself," he tells me.



And maybe that's the part that I will never, ever understand.





(Now, here's Carmichael's e-mail.)







From: David Carmichael

Sent: Tuesday, May 20, 2008 2:35 PM

To: letters@lfpress.com

Subject: Help kill Bill C-51 to prevent many more innocent children like my son Ian from being killed



I have just posted evidence that suggests Paxil, an antidepressant known as a selective serotonin reuptake inhibitor (SSRI), caused me to kill my 11-year-old son Ian on July 31, 2004. It is posted in the "ssri-induced psychosis" section at www.davidcarmichael.com. This evidence was not presented at my first-degree murder trial in September 2005.





I have waited until now to post the evidence that suggests Paxil triggered my psychotic episode, not my major depression, because I was afraid as a Ward of the Lieutenant Governor of Ontario of the close relationship that chemical drug pharmaceutical companies have with government and mental health centres. Tony Clement, for example, owned (and may still own) 25% of a Toronto-based chemical pharmaceutical company between the time he stopped being the Ontario Minister of Health and Long-Term Care (in 2003) and became the federal Minister of Health (in 2006). And in November 2000, Dr. David Healy, a world leading psychiatrist from the U.K. and an expert in psychopharmacology, had his job offer as the Clinical Director of the Mood and Anxiety Disorders Program at the Centre for Addiction and Mental Health (CAMH) rescinded after making a presentation at the University of Toronto on the increased risk of suicide of people on SSRIs.







I am now more afraid of the excruciating pain that many more Canadian families will experience if Bill C-51 is passed than of the consequences of speaking out against Paxil and SSRIs. Bill C-51 has already passed its first reading in the House of Commons.





Bill C-51 is in the best interest of big chemical drug pharmaceutical companies, not in the best interest of the health and safety of Canadians. It provides a provision - amendment 15.1 (2) - based on regulations (which do not require a parliamentary debate or vote) for direct-to-consumer advertising, which will make it easier for big chemical drug pharmaceutical companies to mislead the public about the effectiveness and lethal side-effects of SSRIs. If Bill C-51 is passed, there will likely be many more SSRI-induced suicides and homicides.

Bill C-51 groups natural health products with chemical drugs as "therapeutic products". If Bill C-51 is passed, manufacturers of natural health products, which have not caused a single death in Canadian history, will have to comply with the same rigorous and expensive clinical trial licensing requirements as big chemical drug pharmaceutical companies. This will force many natural health product manufacturers into bankruptcy and may limit mental illness interventions to prescribed psychotropic drugs.

Bill C-51 will make it illegal for anyone to sell or give away up to 60% or more of the natural health products that are currently on the market. Yet, more than 70% of Canadians use natural health products with few adverse side-effects. If Bill C-51 is passed, parents could face criminal charges if they give organic herbs or nutritional supplements that foster mental health to their children.

Bill C-51 does not support mental health promotion. It supports the treatment of mental illnesses with prescribed psychotropic drugs. If Bill C-51 is passed, psychiatrists and medical doctors will have to focus more on the chemical treatment of major depression and other mental illnesses. It will be illegal for them to promote mental health and prevent mental illnesses by prescribing many of the natural health products that are currently on the market.

Bill C-51 will make it easier for Health Canada inspectors to prosecute anyone who sells many of the natural health products that are currently on the market. The maximum fines will increase from $500 to $250,000 for a first time summary offence and from $5,000 to $5,000,000 for an indictable offence. If Bill C-51 is passed, many naturopathic and homeopathic doctors who currently prescribe natural health products that prevent mental illnesses will be forced out of business.

Bill C-51 is a Tony Clement - friend of big pharma - amendment to Canada's Food and Drugs Act. It will force Canadians to spend more than the $22.5 billion they spent on prescribed drugs in 2007 - up 7.2% from $21 billion in 2006.







Bill C-51 has to be killed to prevent many more innocent children like my son Ian from being killed.







Please pressure Members of Parliament (MPs) to vote against Bill C-51.







David Carmichael









See Bill C-51 here
 
3 comments

Mark Harvey, of the solicitors Hugh James - litigants want product label change - compensation secondary

Mark Harvey, of the solicitors Hugh James in Cardiff, who has most of the UK cases, said his clients were most anxious to get an   adequate warning on the drug and research into the dependency problems and aggression they say they have experienced. Compensation for their distress, which in some cases is said to have lasted years and wrecked lives, was a lesser priority.









http://www.mentalhealth.org.uk/information/news/?textonly=1&entryid=49667&entryid17=24655&cord=ASC&p=144

Tuesday, 14 December 2010

Seroxat litigants want product label change - compensation secondary - Mark Harvey

800 hooked on drug seek legal action

Full Story

More than 800 men and women who have found themselves hooked on the antidepressant Seroxat are seeking legal action against the British manufacturers, increasing the pressure for tougher warnings about the drug's side effects. The potential litigants want to force Glaxo SmithKline to change the information it puts out to doctors and patients. They want the company to warn that significant numbers of people can become dependent on the drug - an SSRI (selective serotonin reuptake inhibitor) like Prozac - which GPs often prescribe for relatively minor depression. As the numbers of those seeking action in the UK continue to rise, a row is under way in the United States where a federal court judge has ordered Glaxo to pull television advertisements which state the drug is non-habit forming. Mark Harvey, of the solicitors Hugh James in Cardiff, who has most of the UK cases, said his clients were most anxious to get an   adequate warning on the drug and research into the dependency problems and aggression they say they have experienced. Compensation for their distress, which in some cases is said to have lasted years and wrecked lives, was a lesser priority. Mr Harvey said the cases were still coming in at the rate of around a dozen a day. The scale of the problem was so great that he believed the medicines control agency (MCA), which regulates pharmaceutical drugs, should take action. I have written to the MCA who have continued to say there isn't a problem here because we accept what the companies tell us, he said. The system for reporting adverse drug reactions has never been satisfactory. I have got 800. I suggested they might listen to the stories my clients tell and accept those as reports. Only doctors, and, more recently, pharmacists and some nurses, can send reports of problems with drugs to the MCA through what is known as the yellow card scheme - not the patient who is experiencing the side effects. Only a few doctors ever send in reports, however, and most experts believe the scale of drug-induced illness is under-estimated. Seroxat has topped the league for yellow card reports of withdrawal problems by some distance, with 1,281 reports to date. They can't continue to say there isn't a problem when I have 800 people, said Mr Harvey. The World Health Organisation has said there is a problem. This is like a living clinical trial. The MCA has recently said that it may be willing to consider some way of accepting reports of side effects from patients themselves. Source: The Guardian, Monday September 16, 2002
Release Date 16/08/2002

Venlafaxine and Serious Withdrawal Symptoms: Warning to Drivers

Venlafaxine and Serious Withdrawal Symptoms: Warning to Drivers

http://www.medscape.com/viewarticle/506427

extract

As discussed, withdrawal symptoms occur in patients who have received both low and high doses of venlafaxine and result in a discontinuance syndrome with several manifestations, especially severe dizziness and disorientation, that are incompatible with driving a car or using heavy or dangerous machinery. Although standard warnings are given that taking the drug may affect those abilities, and patients are also generally advised not to stop the medication abruptly, severe withdrawal symptoms, such as confusion, impaired coordination, sensory disturbances, vertigo, delirium, strokelike symptoms, and depersonalization, may occur only hours after reduction or cessation and should warrant a specific "warning to drivers." Whenever venlafaxine is not taken at the usual time or in the usual quantity, special caution is warranted. Even when the dosage is being tapered, the physician should instruct the patient to beware of these symptoms, because the recommended tapering period of 2 weeks is not necessarily sufficient. Cases have been documented in which even tapering over a period of 3 months was insufficient.[16

Dr Aubrey Blumsohn - two day a week NHS job in pathology

Jay Ilangaratne, Founder


www.medical-journals.com

John Stone says, "Dr Aubrey Blumsohn, has long since ceased to work: unemployable for that very reason". However,in this feature article it is said [1],"A two day a week NHS job in pathology was salvaged for him at Sheffield, where he survives on tenuous fixed term contracts".Further, Blumsohn is quoted as saying[1],"I have spent the last 30 years conducting research into the cause,diagnosis, and treatment of osteoporosis,publishing around 295 papers. I am committed to continuing with

More...John Stone says, "Dr Aubrey Blumsohn, has long since ceased to work: unemployable for that very reason". However,in this feature article it is said [1],"A two day a week NHS job in pathology was salvaged for him at Sheffield, where he survives on tenuous fixed term contracts".Further, Blumsohn is quoted as saying[1],"I have spent the last 30 years conducting research into the cause,diagnosis, and treatment of osteoporosis,publishing around 295 papers. I am committed to continuing with medical research....,".Therefore,John Stone's said view does not seem to be compatible with the facts stated in Clare Dyer's article[1].



References



[1]Clare Dyer. Aubrey Blumsohn: Academic who took on industry BMJ 2009; 339: b5293



Competing interests: None declared

http://www.bmj.com/content/339/bmj.b5293.extract/reply#bmj_el_230451

Fiddaman - "Fiddysupport" is failed human being Dr Aubrey Blumsohn

extracts

bob fiddaman’s video about paxil should be seen! and there are several efforts now to get everyone to post his video as a show of solidarity!



on April 3, 2008 at 1:20 pm2 Fiddysupport

•Suggest post another post with the updated links to this here:



source

http://missisyphus.wordpress.com/2008/04/02/bob-fiddamans-video-about-paxil-should-be-seen/


Saturday, 11 December 2010

GSK & Dr Nemeroff - corrections at NY Times - BobFiddaman blogspot

BUSINESS DAY    



http://www.nytimes.com/2010/12/08/pageoneplus/corrections.html


A headline on Nov. 30 with an article about SmithKline Beecham’s role in the publication of a book about treating psychiatric disorders overstated SmithKline’s actions. While documents show that SmithKline (now known as GlaxoSmithKline) hired a writing company for the book, they do not indicate that the company wrote the book for the authors, Dr. Charles B. Nemeroff and Dr. Alan F. Schatzberg. The article also described incorrectly, in some editions, events outlined in a letter from the writing company to Dr. Nemeroff. The correspondence proposed a timeline for the writing company to furnish the doctors and SmithKline with draft text and final page proofs for approval; the letter did not say that the company had already provided those materials for final approval. And the article misstated the context under which Dr. David A. Kessler, the former commissioner of the Food and Drug Administration, commented about the book’s production. The letter and other documents were described to him; he did not personally review the documents. (Go to Article)

Friday, 10 December 2010

Mixed Results in Recent Paxil Lawsuits - win some loose some

Mixed Results in Recent Paxil Lawsuits




Philadelphia, PA: When it comes to a potential Paxil lawsuit, each case must be judged on its own merits. Although some lawsuits alleging serious Paxil side effects, such as Paxil birth defects, have been settled, others have been dismissed from court.




In July 2010, GlaxoSmithKline, maker of Paxil, reportedly settled approximately 800 lawsuits alleging Paxil birth defects for around $1 billion. The lawsuits reportedly alleged that Paxil caused birth defects in babies who were exposed to the antidepressant before their birth. At the time, The Wall Street Journal (7/20/10) quoted an e-mail from GlaxoSmithKline as saying the company "has reached an agreement to settle certain cases involving the use of Paxil during pregnancy. The details of those settlements are confidential. Other cases remain pending."



One such pending case was that of Anna Blyth, whose lawsuit alleged that she (now 14 years old) was born with cardiac birth defects that were caused by her mother's use of Paxil while pregnant. The lawsuit alleged that GlaxoSmithKline failed to warn that the use of Paxil could result in birth defects. Anna was born with a narrowing of her aorta.



GlaxoSmithKline defended itself, saying it acted responsibly in studying Paxil and marketing the antidepressant for use. The company also argued that Anna did not suffer any long-term negative effects from her heart problems.



The judge in that case dismissed the lawsuit halfway through the trial.



In another case, however, the family of a boy who died approximately six weeks after birth reached a settlement with GlaxoSmithKline for an undisclosed amount. The lawsuit, which was filed by Jennifer Berg, alleged that the use of Paxil during her pregnancy resulted in her son being born with persistent pulmonary hypertension of the newborn (PPHN), which ultimately resulted in his death.



Persistent pulmonary hypertension of the newborn (previously called primary pulmonary hypertension of the newborn), is a life-threatening condition in which the baby's circulatory system does not properly adapt to breathing on its own. The result is that blood does not properly reach the lungs, which prevents oxygenated blood from being circulated throughout the baby's body.



Symptoms of PPHN include rapid breathing, rapid heart rate, low oxygen levels and respiratory distress.



Paxil is an antidepressant in a class of drugs known as selective serotonin reuptake inhibitors (SSRIs).

WikiLeaks cables: Pfizer used dirty tricks to avoid clinical trial payout - http://t.co/XjbbYBT - via @guardian

WikiLeaks cables: Pfizer used dirty tricks to avoid clinical trial payout http://t.co/XjbbYBT via @guardian







or

http://www.guardian.co.uk/business/2010/dec/09/wikileaks-cables-pfizer-nigeria?CMP=twt_gu

WikiLeaks cables: Pfizer used dirty tricks to avoid clinical trial payout


Cables say drug giant hired investigators to find evidence of corruption on Nigerian attorney general to persuade him to drop legal action



•

◦

◦Share

◦

◦

•Comments (89)

•Sarah Boseley, health editor

•guardian.co.uk, Thursday 9 December 2010 21.33 GMT

•Article history

Kano, in northern Nigeria, saw a meningitis epidemic of unprecedented scale in 1996. Photograph: Pius Utomi Ekpei/AFP/Getty Images The world's biggest pharmaceutical company hired investigators to unearth evidence of corruption against the Nigerian attorney general in order to persuade him to drop legal action over a controversial drug trial involving children with meningitis, according to a leaked US embassy cable.



Pfizer was sued by the Nigerian state and federal authorities, who claimed that children were harmed by a new antibiotic, Trovan, during the trial, which took place in the middle of a meningitis epidemic of unprecedented scale in Kano in the north of Nigeria in 1996.



Last year, the company came to a tentative settlement with the Kano state government which was to cost it $75m.



But the cable suggests that the US drug giant did not want to pay out to settle the two cases – one civil and one criminal – brought by the Nigerian federal government.



The cable reports a meeting between Pfizer's country manager, Enrico Liggeri, and US officials at the Abuja embassy on 9 April 2009. It states: "According to Liggeri, Pfizer had hired investigators to uncover corruption links to federal attorney general Michael Aondoakaa to expose him and put pressure on him to drop the federal cases. He said Pfizer's investigators were passing this information to local media."



The cable, classified confidential by economic counsellor Robert Tansey, continues: "A series of damaging articles detailing Aondoakaa's 'alleged' corruption ties were published in February and March. Liggeri contended that Pfizer had much more damaging information on Aondoakaa and that Aondoakaa's cronies were pressuring him to drop the suit for fear of further negative articles."



The release of the Pfizer cable came as:



• The American ambassador to London denounced the leak of classified US embassy cables from around the world. In tomorrow'sGuardian Louis Susman writes: "This is not whistleblowing. There is nothing laudable about endangering innocent people. There is nothing brave about sabotaging the peaceful relations between nations on which our common security depends."



• It emerged that Julian Assange had been transferred to the segregation unit in Wandsworth prison and had distanced WikiLeaks from cyber attacks on MasterCard, Visa, PayPal and other organisations.



• Other newly released cables revealed that China is losing patience with the failure of the Burmese regime to reform, and disclosed US fears that Europe will cave in to Serbian pressure to partition Kosovo.



While many thousands fell ill during the Kano epidemic, Pfizer's doctors treated 200 children, half with Trovan and half with the best meningitis drug used in the US at the time, ceftriaxone. Five children died on Trovan and six on ceftriaxone, which for the company was a good result. But later it was claimed Pfizer did not have proper consent from parents to use an experimental drug on their children and there were questions over the documentation of the trial. Trovan was licensed for adults in Europe, but later withdrawn because of fears of liver toxicity.



The cable claims that Liggeri said Pfizer, which maintains the trial was well-conducted and any deaths were the direct result of the meningitis itself, was not happy about settling the Kano state cases, "but had come to the conclusion that the $75m figure was reasonable because the suits had been ongoing for many years costing Pfizer more than $15m a year in legal and investigative fees".



In an earlier meeting on 2 April between two Pfizer lawyers, Joe Petrosinelli and Atiba Adams, Liggeri, the US ambassador and the economic section, it had been suggested that Pfizer owed the favourable outcome of the federal cases to former Nigerian head of state Yakubu Gowon.



He had interceded on Pfizer's behalf with the Kano state governor, Mallam Ibrahim Shekarau – who directed that the state's settlement demand should be reduced from $150m to $75m – and with the Nigerian president. "Adams reported that Gowon met with President Yar'Adua and convinced him to drop the two federal high court cases against Pfizer," the cable says.



But five days later Liggeri, without the lawyers present, enlarged on the covert operation against Aondoakaa.



The cable says Liggeri went on to suggest that the lawsuits against Pfizer "were wholly political in nature".



He alleged that Médecins sans Frontières, which was in the same hospital in Kano, "administered Trovan to other children during the 1996 meningitis epidemic and the Nigerian government has taken no action".



MSF – which was the first to raise concerns about the trial – vehemently denies this. Jean-Hervé Bradol, former president of MSF France, said: "We have never worked with this family of antibiotic. We don't use it for meningitis. That is the reason why we were shocked to see this trial in the hospital."



There is no suggestion that the attorney general was swayed by the pressure. However, the dropping of the federal cases provoked suspicion in Nigeria. Last month, the Nigerian newspaper Next ran a story headlined, "Aondoakaa's secret deal with Pfizer".



The terms of the agreement that led to the withdrawal of the $6bn federal suit in October 2009 against Pfizer "remain unknown because of the nature of [the] deal brokered by … Mike Aondoakaa", it said. Pfizer and the Nigerian authorities had signed a confidentiality agreement. "The withdrawal of the case, as well as the terms of settlement, is a highly guarded secret by the parties involved in the negotiation," the article said.



Aondoakaa expressed astonishment at the claims in the US cable when approached by the Guardian. "I'm very surprised to see I became a subject, which is very shocking to me," he said. "I was not aware of Pfizer looking into my past. For them to have done that is a very serious thing. I became a target of a multinational: you are supposed to have sympathy with me … If it is true, maybe I will take legal action."



In a statement to the Guardian, Pfizer said: "The Trovan cases brought by both the federal government of Nigeria and Kano state were resolved in 2009 by mutual agreement. Pfizer negotiated the settlement with the federal government of Nigeria in good faith and its conduct in reaching that agreement was proper. Although Pfizer has not seen any documents from the US embassy in Nigeria regarding the federal government cases, the statements purportedly contained in such documents are completely false.



"As previously disclosed in Pfizer's 10-Q filing in November 2009, per the agreement with the federal government, Nigeria dismissed its civil and criminal actions against the company. Pfizer denied any wrongdoing or liability in connection with the 1996 study. The company agreed to pay the legal fees and expenses incurred by the federal government associated with the Trovan litigation. Pursuant to the settlement, payment was made to the federal government's counsel of record in the case, and there was no payment made to the federal government of Nigeria itself. As is common practice, the agreement was covered by a standard confidentiality clause agreed to by both parties."

Thursday, 9 December 2010

Citalopram suicides 5x times greater than Seroxat

Toxicity of antidepressants: rates of suicide

relative to prescribing and non-fatal overdose

Keith Hawton, Helen Bergen, Sue Simkin, Jayne Cooper, Keith Waters, David Gunnell
and Navneet Kapur

The British Journal of Psychiatry (2010)


196, 354–358. doi: 10.1192/bjp.bp.109.070219

Wednesday, 8 December 2010

Group Actions - Another one bites the dust

Another one bites the dust

http://www.thelawyer.com/another-one-bites-the-dust/76810.article

With the failure of yet another group action - this time the army veterans' claim against the MoD - the costs argument is overshadowing the real issues. Are defendants being given an easy way out? Jon Robins reports




The three Ds - disappointed, dismayed and devastated, is how Trevor Ward, senior partner at Manchester firm Linder Myers, sums up the range of emotions he feels as a result of the judgment last week that brought to an abrupt halt the potential claims of some 2,000 former servicemen and women in the High Court for psychiatric injuries resulting from the stress and trauma of combat. No doubt many claimant lawyers will share his feelings at the collapse of yet another group action.



"I'm devastated. Not for myself - we've tried to do a good job, it's failed, and yes, I'll have sleepless nights about that," Ward says. "But I'm devastated for those people who were relying on what they considered to be a just judgment coming out of this. They have nowhere else to go."



A large section of the claimants who served in the Falklands, Northern Ireland, Bosnia and the Gulf War were barred under a statutory immunity that applied up to 1987, while other subsequent claims were defeated because of 'combat immunity', which the judge found still applied for activities that took place well away from any live military action. Mr Justice Owen also looked closely at 15 'lead' cases, and in only four of these did he decide that the Ministry of Defence (MoD) was in breach of its duty of care. But he concluded that such cases "turned on their own facts, and do not demonstrate a systematic failure on the part of the MoD".



So the vast majority of the veterans' cases look set to join a dismal roll call of failed group actions, which includes last year's oral contraception pill (OCP) litigation, which dramatically fell apart last year following 44 days of legal argument and the contributions of 10 epidemiologists. Both actions represent an achievement of sorts in this increasingly difficult area of the law insofar as they at least made it to the courtroom door. The veterans' action has the unique distinction of being the only big multiparty action in recent years to survive a full trial, in this case six months in the High Court.



For 4,000 people who have found themselves hooked to the antidepressant Seroxat, the prospects of getting that far seem pretty remote after a recent decision to remove public funding.



In the wake of the OCP ruling, Martyn Day, senior partner at Leigh Day & Co, who represented nearly 100 women in the action, declared flatly that "the system just doesn't work" for these most groundbreaking of cases. Of course, the long list of disastrous group actions can be traced back to the failed Norplant contraceptive litigation, Day's (and Irwin Mitchell's) attempts to take on the tobacco companies in 1999 and, of course, the notorious benzodiazepine tranquilliser cases, which swallowed up £30m of taxpayers' money without seeing the inside of a courtroom.



"It's a real worry that judges just don't seem to like these cases," Day says. "I'm of the view that our judges have been very conservative and the consistent failures, together with the costs, could effectively mean that they end up just never being pursued."



Ward, who like Day is a veteran of multiparty actions, does not share such a pessimistic view. "It's difficult to get these cases off the ground because so much preparation has to be done, and getting funding has become more and more difficult," he acknowledges. But there should and "probably always will be funding" for those cases that are in the public interest and are "proven to be of reasonable merit". The problem, he adds, is getting there.



"The other difficulty is that it remains to be seen how many more cases the Lord Chancellor's Department and the Treasury are going to allow to be lost," Ward continues. "We didn't anticipate we'd lose this, but it's a big sting for the taxpayer's purse."



Even the mention of the benzo fiasco elicits a scream of mock horror from Ward. He is at great pains to point out how carefully managed the MoD Post-Traumatic Stress Disorder (PTSD) case was. From the outset, specific generic issues were broken down between the parties - such as the state of knowledge of the MoD about PTSD, whether there was an effective treatment available at the time, the nature of the duty of care owed on discharge from the forces - and it was agreed that costs were to follow the success of each individual issue.



"In theory we could win one issue, and if 90 per cent of the costs of trial revolved around that issue, we might lose the trial but win on costs," he explains. A large part of the MoD's £3.5m estimated costs and the claimants' £5.5m costs was spent on the treatment issue, which took a month of the High Court's time, and was won by the claimants. "It might be that the costs consequences aren't that drastic for the Legal Services Commission [LSC]," Ward adds.



The claimants also agreed at the onset of the action not to publicise it and concentrate energies on identifying issues for the trial. As a quid pro quo, the defendants agreed a 'limitation holiday' to allow later claims to join the action without being statute barred. Some 1,700 potential claimants signed up to what was called 'register two' and they, according to Ward, were just "names on a list" who did not sign up to any costs-sharing order.



There remains the possibility of an appeal, as the claimants dispute parts of the judge's findings - in particular as to what the military should have known and should have done to relieve its responsibilities. "We'll have to stand back and carefully consider whether, aside from being disappointed and dismayed by some of the judge's comments, in reality those points are capable of being overturned, or they are so wrong as to be the subject of an appeal," Ward adds.



In fact, last week saw a double blow for claimants as a controversial costs ruling in the multiparty action concerning organ retention sent shockwaves through the profession. The defendants had asked for costs (excluding those in the Alder Hey scandal) to be capped both retrospectively from February 2003 and up until the trial next January. The claimant firm Alexander Harris Solicitors estimated that from February it had incurred costs of £1.45m, and would expect another £1m to get to the end of trial. An average hourly rate of £155 per hour was agreed.



However, Mr Justice Gage, advised by senior costs judge Peter Hurst, took issue with the firm's suggestion that it needed 3,410 hours on the cases. "On strictly generic issues, [the claimants'] figure represents a substantial overestimate of what is fair and reasonable and proportionate," the judge ruled. In what was described as a "novel procedure", he capped the total budget to £506,500 and the fees at £271,250 on the grounds that 'prospective budget setting' came under the court's case management powers.



Such judicial thinking represents a "fairly sinister development", reckons Mark Harvey, a partner at South Wales firm Hugh James and secretary of the Association of Personal Injury Lawyers (Apil). "The defendant generally has deeper pockets than the claimant and my concern is that it's like a David-and-Goliath contest and then taking the sling off David," he continues. The judgment is all the more extraordinary, he argues, in light of the recent inability of parties to agree on the relatively simple issue of establishing the level of fixed fees in low value road traffic cases. "To start doing this in complex group actions just seems completely wrong," he says.



Alexander Harris partner David Harris, representing the claimants in the action, explains that they agreed to the approach on the basis that the idea of a costs cap was specific to this litigation. "It was not to be taken by us that there was a power of the court to make such an order - although I think there probably is - or that it should be treated as some form of precedent for any other case," he says. "But it's clear to me that this ruling isn't just going to have repercussions in group cases - it goes for multitrack cases as well."



Harris acknowledges that the figures his firm initially quoted for generic costs were "unfortunate", and explains that they represented the greatest possible sums they might have expected to recover, as distinct from what they expected to.



Claimant lawyers see the prospect of such costs applications being routinely used as another weapon in the defendant armoury that, in the case of the big drugs companies and the likes of the MoD, is already massively disproportionate.



"The defendants are using every single opportunity to attack costs anyway," argues Day at Leigh Day. "We have seen that in the CFA [conditional fee arrangement] debate and now here it is in relation to group claims. The judges seem to feel you should have some magic idea about what exactly these costs are going to be in cases that are very difficult to judge. The pressure on claimant firms in these areas is getting more and more intense at a time when few cases succeed anyway."



At the moment all eyes are on the progress of the Measles, Mumps and Rubella (MMR) group action linking the vaccine with autism. Alexander Harris is advising 800 families in an action over MMR. In terms of public funding, this is the largest publicly-funded case since the benzo case and the families will not only have to take on the might of the drugs companies but Government policy as well.



According to Harris, funding is not such a problem, as the case predates the 1999 reforms of the legal aid system. However, the imbalance between claimants and defendants will, of course, be huge. "There was one case management conference where the defendant had 62 lawyers in court and we reckon that there were 42 in the last one," he reports. "The wealth and power of these drugs companies is just beyond belief."



Of course, not all group actions fail. Harris points to his firm's own success against GlaxoSmithKline, the manufacturer of Myodil, which caused a painful and debilitating back disorder, as well as the victory by Newcastle upon Tyne firm Deas Mallen for more than 100 people infected with the hepatitis C virus through blood transfusions, who won compensation totalling millions of pounds in March 2001. "But the fact is that there have been two big cases that have gone to trial and lost recently and that's depressing," he adds. "It's going to make the Legal Services Commission even more controlled in their financial expectations."



"I was astonished that they didn't win," says Hugh James's Harvey of last week's High Court ruling against the veterans. But he also points out that, away from the product liability cases and the complexity of PTSD-style cases, group actions are won on a regular basis. In fact, according to Harvey, his practice has yet to lose one. He counts among his successes actions on behalf of miners suffering respiratory diseases and vibration white finger; two recent nuisance actions for claims relating to waste pits; he recently successfully represented passengers on an ill-fated Britannia Airways flight that crash-landed in Gerona Airport in September 1999; he is heading up the Seroxat action and, despite the LSC having pulled the plug, he is expecting to issue a letter of claim in the next few weeks.



"The great problem remains in relation to the defendants' ability to recover costs, because no matter how keen a firm is, if our client is faced with the prospect of those costs - and in the OCP litigation costs were in the region of £10m - you can't possibly expose clients to that," says Harvey. The already nervous legal expenses insurance market is not likely to touch such claims. As Harvey says: "There still remains a great question mark over the most complex cases. It's quite clear that the Government has no intention to provide the safety net of legal aid, despite the fact that it said there would be."



The risk for law firms using conditional fees in this area was vividly illustrated by Leigh Day's and Irwin Mitchell's attempts to sue the tobacco companies. "No win, no fee, and possible bankruptcy," was how Day memorably described his funding mechanism of choice for that ill-fated action. At the end of the day, his firm faced costs estimated to be in the region of £2.5m. He would not commit to such a case again without the backing of insurance. According to Day: "It was a really traumatic experience knowing that the clients faced bankruptcy even though they were impecunious people. I wouldn't go through that again."



As for Day's response to the latest events, he says: "The landscape for group actions is pretty gloomy and these dark clouds which have been gathering overhead just keep getting worse and worse."

Natural news just another CCHR Scientology front ?

Paxil / Seroxat - are you pregnant - do NOT take - 1995 - the evidence is clear

Paxil / Seroxat - are you pregnant - do NOT take - 1995












GSK warn about Seroxat / pregnancy in 1995  







source



http://www.itri.brighton.ac.uk/projects/pills/corpus/PIL/data/SmithKline_Beecham/Seroxat/Seroxat.html

What you should know about 'Seroxat' Tablets




This leaflet tells you about your tablets. Please read it before you start taking them. If there is anything you do not understand, or you want to KNOW more about your tablets, ask your doctor or pharmacist (chemist).



Please keep this leaflet You may want to read it again.



WHAT IS IN YOUR TABLETS?



Each ‘Seroxat’ tablet contains paroxetine hydrochloride.



Each pack contains 30 tablets of either 20 mg or 30 mg doses.



The tablets also contain inactive ingredients These are E464, E341, E572 and sodium starch glycollate. The tablets are also coated with Opadry YS-I-7003 and Opadry YS-I-7006 (20 mg tablets) or Opadry YS-I-4256 and Opadry YS-I-7006 (30 mg tablets). These coating materials contain E464.



WHO MAKES ‘SEROXAT’?



‘Seroxat’ Is made by SmithKline Beecham Pharmaceuticals, Manor Royal, Crawley, Sussex.



Product Licence holder: SmithKline Beecham plc, Brentford, trading as SmithKline Beecham Pharmaceuticals, Welwyn Garden City, Herefordshire, England AL7 1EY.



Product Authorisation holder: SmithKline Beecham (Ireland) Ltd., Dun Laoghaire, Co. Dublin.



WHAT IS ‘SEROXAT’?



'Seroxat' Is an anti-depressant medicine. It works by relieving the symptoms of depression and any associated anxiety. These tablets are not addictive. Everyone has a substance called serotonin in their brain. Low levels of serotonin are thought to be a cause of depression, and other related conditions. This medicine works by bringing the levels of serotonin in your brain back to normal.



BEFORE YOU TAKE ‘SEROXAT’



If you answer "YES" to any of the following questions, DO NOT take this medicine. Go back to your doctor and ask what to do:



Are you allergic to paroxetine?

Are you pregnant or may you be pregnant soon?

Are you breast feeding?

Are you under 18?

Do you have kidney o, liver trouble?

Do you have heart trouble?

Do you suffer from epilepsy or mania (overactive and sometimes violent behaviour)?

Most people find that 'Seroxat' does not affect their normal daily lives. But, as with many medicines you should take extra care when you ere driving or operating machinery



CAN YOU TAKE ‘SEROXAT’ WHILE TAKING OTHER MEDICINES?



Always tell your doctor about any medicines you are taking. This means medicines you have bought for yourself as well as medicines the doctor has prescribed for you.



‘Seroxat’ may affect: other antidepressants, medicines containing tryptophan, medicines used to prevent fits (anti-convulsants); medicines used to thin the blood (anti-coagulants), and medicines used to treat other psychiatric conditions. You should not take ‘Seroxat' if you are taking monoamine oxidase inhibitors (MAOls), or if you have taken them within the last 2 weeks. If you are taking any other medicines, check with your doctor or pharmacist before taking ‘Seroxat’. They will know if it is safe for you to do so. You should avoid alcohol while you are taking this medicine.



HOW TO TAKE YOUR TABLETS



Take the dose that your doctor has recommended. You will find this on the pharmacist’s label. This is usually one tablet a day (the highest dose is 50 mg each day). Take ‘Seroxat' each morning after you have eaten. Swallow the tablets whole with a drink of water. Do not suddenly stop taking your tablets without discussing this with your doctor



50136GB1









Some people find that if they suddenly stop taking these tablets, they feel dizzy shaky sick anxious confused or have tingling sensations. They may also have difficulty sleeping and vivid dreams when they do sleep. But these symptoms are unusual and generally disappear after a few days. To avoid these symptoms your doctor may tell you to take smaller doses or to spread doses further apart before you stop taking the tablets altogether



HOW LONG SHOULD YOU TAKE ‘SEROXAT’ FOR?



Like any other anti-depressant 'Seroxat' will not relieve your symptoms straight away. You should start to feel better after a week or two, although it may take longer. Even after you start to feel better it’s important to keep taking your tablets for as long as your doctor recommends. This may be a number of months, but be patient. If you stop taking your tablets too soon, your symptoms may return. Remember that you cannot become addicted to 'Seroxat'.



WHAT IF YOU MISS A DOSE?



Leave out the dose completely. Take your next dose at the normal time.



It is important to take the tablets each day until they are finished.



WHAT IF YOU TAKE TOO MANY TABLETS?



You should never take more tablets then your doctor recommends. If you take too many 'Seroxat' tablets, tell your doctor or hospital casualty department straight away. Show them your pack of tablets.



DOES ‘SEROXAT’? CAUSE SIDE EFFECTS?



Any medicine can cause unwanted effects. With 'Seroxat', any side effects are usually mild and go away after the first few weeks of treatment. The most likely side effect of ‘Seroxat' is that you may feel slightly sick. Taking your medicine In the morning after food will reduce the chance of this happening. When taking 'Seroxat' some people may have an upset stomach, a rash, or a dry mouth. They may sweat more than usual, or feel drowsy but be unable to sleep soundly. They may also have some sexual problems that will go away when they stop taking the tablets. Patients can occasionally feel dizzy shaky or restless, or they may feel faint when they stand up . Very rarely, patients may experience jerking movements or sudden mood changes. There may also be a slight chance that your body's salt balance or any tests for liver function are affected for a while. If you have any problems while taking 'Seroxat', tell your doctor or pharmacist.



LOOK AFTER YOUR TABLETS



Keep your tablets in the pack with this leaflet. Keep them in a place where children cannot see or reach them. Do not take your tablets after the "expiry" date shown on the pharmacist’s label. Never give these tablets to others. You could harm them, even if they have similar symptoms to you. Finish all your tablets as the doctor tells you to.



MORE INFORMATION ABOUT DEPRESSION



Depression is a common illness. At any one time, one in 20 people will be suffering from it. The balance of chemicals in the brain is also thought to affect the way we feel. Serotonin is one of these chemicals, and appears to be at low levels in people who are depressed. For the first week or two after you start taking your tablets, you may still find that things will be difficult. This is because it takes a while for your tablets to rebalance the serotonin in your brain. But, once this starts to happen, you will notice the difference.



It is important that, even when you begin to feel better, you keep taking your tablets until your doctor tells you to stop. This will reduce the chance of your depression returning.



REMEMBER



Depression is a common illness. It is nothing to be ashamed of.



It is not a sign of weakness. It can be treated successfully.



Now that you have seen your doctor, found out what is wrong, and discovered it can be treated, you are already starting to get better



SmithKline Beecham Pharmaceuticals has developed a Patient Support Programme designed to offer help and support to sufferers of depression and their partners, friends and relatives. The service is free and provides educational information to help you on the road to recovery. To join the Patient Support Programme simply write to:



Freepost, CV768, RUGBY, Warwickshire CV22 7BR.



Or call our pre-recorded information line where you will be invited to leave your name and address:



PHONELINE NO: 0645 406080



All calls will be charged at local rate.



Date this leaflet was prepared: June 1995.



© 1995 SmithKline Beecham Pharmaceuticals



'Seroxat' is a registered trade mark

Sunday, 5 December 2010

Dr Andrew Isaacs of the Seroxat Users Group - video

http://news.bbc.co.uk/1/hi/programmes/breakfast/3176550.stm







click here to watch Breakfast's debate on Seroxat in full

GSK statement on dismissal of Paxil product liability trial in Philadelphia Court of Common pleas

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.




GSK statement on dismissal of Paxil product liability trial in Philadelphia Court of Common pleas  



http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10100.htm

Issued: November 22, 2010, Philadelphia, PA



On November 22, 2010, a Philadelphia judge entered judgment in favor of GSK and dismissed a case alleging that use of Paxil during pregnancy caused 14-year-old Anna Blyth to be born with certain cardiac birth defects.



GSK is gratified by Judge Glazer's dismissal of the case.



Unfortunately, birth defects occur in three to five percent of all live births, whether or not the mother was taking medication during pregnancy.



GSK believes it acted properly and responsibly in researching and studying Paxil, including sharing documentation and submitting results from studies on Paxil to regulators. We also believe that once approved for use, the company acted properly in marketing the medicine, including monitoring its safety, updating pregnancy information in the medicine's labeling as new information became available and communicating important safety information to regulatory agencies, the scientific and medical community and the public.



GSK will continue to vigorously defend this litigation and will try cases where appropriate.



GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information go to us.gsk.com, follow us on twitter.com/GSKUS or visit our blog (www.morethanmedicine.us.gsk.com/blog/).

Saturday, 4 December 2010

Paxil Birth Defect Trial Tossed Out of Court



Summerville, SC: It was a heartbreaking end to a Paxil birth defects trial in Philadelphia, after a judge ended the proceedings at about the midway point, finding for GlaxoSmithKline (Glaxo), the defendant. The lawsuit, the first Paxil trial to be undertaken since Glaxo agreed in July to settle 800 cases by paying out more than $1 billion, attempted to determine whether Paxil caused a birth defect suffered by Anna Blyth.


http://www.lawyersandsettlements.com/articles/15497/paxil-birth-defects-side-effects-pph-9.html

Bloomberg News reported in November that the family's Paxil lawyer stated during trial it was the family's belief Paxil was responsible for a narrowing of the aorta leading from the heart of Anna Blyth, now 14. Further, the plaintiffs accused Glaxo as having in their possession research dating back to the 1980s showing Paxil as the root cause of deaths amongst the offspring of animal test subjects—but that Glaxo failed to provide warnings about the deaths.



According to Bloomberg, Paxil was approved for use by the US Food and Drug Administration (FDA) in 1992, three years before the plaintiff's mother, Marsha, was prescribed Paxil for a short time during her pregnancy, for depression.



Anna required two open-heart surgeries within nine months of her birth, according to the plaintiff's legal team.



Glaxo countered at trial that the label for Paxil contained "all the knowledge it had as of 1995," with regard to the potential risks of Paxil side effects for pregnant women. The manufacturer also noted that Anna Blyth had grown into a vibrant 14-year-old, an honor's student who plays volleyball and indulges in tae kwon do with no apparent lasting effects from her early health problems.



The defendant lobbied the presiding judge to dismiss the action, which State Court Judge Gary Glazer did—effectively ending the trial. It is not known if the Blyth family, which was not part of the earlier Glaxo settlement in July, will appeal the verdict.



Bloomberg reported that 15 additional Paxil cases against Glaxo alleging Paxil birth defects are slated for Philadelphia next year. Some birth defects allegedly linked to Paxil have been severe, resulting on occasion in Paxil infant death.

Paxil / Seroxat - Dismissal Granted in Paxil birth defect case Case - but don't expect Bob to tell you !!

Dismissal Granted in Paxil Case


Anna Blyth's case against GlaxoSmithKline, the makers of the popular antidepressant drug Paxil, has been dismissed by a Philadelphia judge.

http://www.productliabilityattorneyblog.com/2010/11/dismissal_granted_in_paxil_cas.html

In the case, Blyth alleged that taking Paxil during her pregnancy caused her now 14-year-old daughter Anna to be born with specific cardiac birth defects. Part of Glaxo's defense strategy was to state that while unfortunate, 3-5 percent of all live births today are to children with birth defects. They also stated that this happens with and without the mother having taken medications during the pregnancy.  



Glaxo officials have stated before that they don't think they did anything wrong in how they researched and studied Paxil. This includes how they shared the information that these studies produced with various regulators like the FDA. Glaxo claims that after Paxil had been granted approval from the FDA for use, the company acted correctly when marketing the prescription medication. This included how Glaxo monitored its safety, and how it updated the information on how it is used during pregnancy.



All of the information on Paxil's label was said by Glaxo to be new information that was available at the time. The company said that it put everything on the labels as soon as new information was made available. Glaxo officials also say they submitted all new data to regulators, the public and the medical community. For these reasons, the company believes it should not be held liable for Anna's birth defects.



The judge in this case apparently agreed with Glaxo and granted the dismissal. This case is cause for Glaxo to celebrate big time since it has lost or settled many of its recent lawsuits and has been forced to pay more than $1 billion in settlements and fees. But the jury remains out on whether this case will set the precedence for future birth defects cases against Glaxo since the Blyth case is the first of its kind to come to trial.



Posted by Carey, Danis & Lowe, L.L.C.

What Impact Will Paxil Lawsuits Have on Potential Effexor Lawsuits?

http://www.lawyersandsettlements.com/articles/15520/effexor-birth-defects-pregnancy-12.html

Wednesday, 1 December 2010

Baum Hedlund named as Scientology attorneys


Baum Hedlund named as Scientology attorneys - note CCHR lost against Lilly






Know the Attorneys for Scientology: knowledge is key!



George “Skip” William Murgatroyd III 61y attorney (PTS/SP '88, patron '06) (UT) (Tracey Forbes Murgatroyd 58y (Solo Nots I '97), ex-w: Joy L. Callahan, Jack William Murgatroyd (TR '05), f:George W. Murgatroyd II b:12-4-16 d:3-15-99



CCHR (lost against Eli Lilly pharma. Company)

Coale, Kananak & Murgatroyd

6956 Dume Drive

Malibu, CA 90265-4227 (310) 457-6035 skipmurgatroyd@hotmail.com



Michael Lin Baum 57 years old Clinton, OK, attorney (119511)(D.C.) unindicted co-conspirators (Operation SnowWhite, 'so scientology can have snow white hands' steals federal documents about Hubbard and scientology) (Melissa J. Sirkel Baum 43y)



Baum, Hedlund, Aristei, Schiavo law firm



Paul James Hedlund 63 years old (wife is Marta Louise (Brewer) Hedlund 52y teacher at Rosemont Middle School), ex-wife is Marie Olga (Kiraly) Hedlund 62



J. Clark Aristei

Gary Alan Brown 59 years old (litigant assistant, OSA, Integrity '87)

12100 Wilshire Blvd., Suite 950,

Los Angeles, CA 90025-7106 310-207-3233